Hope for patients in need
Currently enrolling: ZB131 Phase 1/2 clinical trial
ClinicalTrials.gov Identifier: NCT05074472
About the ZB131 clinical trial
ZB131 is a monoclonal antibody that binds to cancer cells with cancer-specific plectin (CSP) on their surface, inducing a form of programmed cell death. For more information about monoclonal antibody treatments for cancer, click here.
This study is for people who meet the following eligibility criteria:
- Have advanced or metastatic pancreatic, ovarian, or bile duct cancer
- Are 18 years of age or older
- Have failed all available therapies or are ineligible for standard of care treatment
Your doctor or healthcare provider can help determine if you may be a good fit for the ZB131 clinical trial. For a complete list of eligibility criteria, see ClinicalTrials.gov.
- Potential participants will start with a screening visit to confirm their eligibility for the study. The staff at the trial site will take patients’ medical history and perform a physical exam to ensure they meet the study requirements.
- ZB131 will be administered via IV every week at one of our trial sites.
- During study visits, participants will undergo tests and procedures in addition to those that are part of regular care for their type of cancer to study the treatment’s effect.
Your doctor or a healthcare provider can help you determine if you are eligible for this trial. You can also email email@example.com or the contact for the site most convenient to you for more information.
Yes. All participants will receive ZB131 as part of this study.
Yes. You will have to visit one of our study sites weekly for IV infusions of ZB131.
The study drug ZB131 will be provided to you at no cost. ZielBio will also cover all associated exams and reasonable travel costs. You will not receive other compensation for participation.
Yes. Taking part in this clinical trial is voluntary and entirely up to you.
At this time, ZielBio is unable to provide ZB131 to patients outside the study.
Clinical trial resources